{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:06:06Z","timestamp":1759017966693,"version":"3.44.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T00:00:00Z","timestamp":1601769600000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.annder.2019.06.002","type":"journal-article","created":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T23:13:45Z","timestamp":1564269225000},"page":"646-654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u00c9ruption nodulo-kystique induite par le soraf\u00e9nib"],"prefix":"10.1016","volume":"146","author":[{"given":"A.","family":"Chambelland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-C.","family":"Koeppel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Desmedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Fongue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-P.","family":"Buono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Berbis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Delaporte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2019.06.002_bib0180","doi-asserted-by":"crossref","first-page":"217e1","DOI":"10.1016\/j.jaad.2014.04.013","article-title":"Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: part II. Targeted therapy","volume":"71","author":"Reyes-Habito","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.06.002_bib0185","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.annder.2007.12.006","article-title":"Cutaneous side effects of sorafenib and sunitinib","volume":"135","author":"Autier","year":"2008","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.06.002_bib0190","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","article-title":"Cutaneous adverse effects of targeted therapies: Part I: inhibitors of the cellular membrane","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.06.002_bib0195","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/jamadermatol.2017.5733","article-title":"Erythema nodosum-like eruption in the setting of sorafenib therapy","volume":"154","author":"Coleman","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2019.06.002_bib0200","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaad.2009.02.004","article-title":"Array of cutaneous adverse effects associated with sorafenib","volume":"61","author":"Kong","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.06.002_bib0205","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1365-4632.2008.03598.x","article-title":"A distinctive cutaneous reaction to sorafenib and a multikinase inhibitor","volume":"47","author":"Joncas","year":"2008","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.annder.2019.06.002_bib0210","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D34RG64357","article-title":"Facial acneiform rash associated with sorafenib","volume":"15","author":"Fleta-As\u00edn","year":"2009","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.annder.2019.06.002_bib0215","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/jdv.12720","article-title":"Acquired perforating dermatosis associated with sorafenib therapy","volume":"30","author":"Severino-Freire","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.06.002_bib0220","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/ajd.12207","article-title":"Delayed onset perforating folliculitis associated with sorafenib","volume":"55","author":"Batalla","year":"2014","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.annder.2019.06.002_bib0225","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s13555-014-0067-9","article-title":"Sorafenib-associated facial acneiform eruption","volume":"5","author":"Cohen","year":"2015","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.annder.2019.06.002_bib0230","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/ced.12257","article-title":"Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib","volume":"39","author":"Pichler","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.annder.2019.06.002_bib0235","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1111\/bjd.15982","article-title":"Image Gallery: sorafenib-induced acne of the buttocks","volume":"177","author":"Kiritsi","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2019.06.002_bib0240","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/0394632017727618","article-title":"Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: an unconventional skin reaction requiring unconventional treatment","volume":"30","author":"Borgia","year":"2017","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.annder.2019.06.002_bib0245","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11912-013-0308-6","article-title":"Dermatological adverse events from BRAF inhibitors: a growing problem","volume":"15","author":"Belum","year":"2013","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.annder.2019.06.002_bib0250","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaad.2014.07.033","article-title":"Cutaneous adverse effects of targeted therapies: Part II: inhibitors of intracellular molecular signaling pathways","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.06.002_bib0255","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/DAD.0b013e31828cf3b7","article-title":"Perforating folliculitis in a patient treated with nilotinib: a further evidence of C-kit involvement","volume":"36","author":"Llamas-Velasco","year":"2014","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.annder.2019.06.002_bib0260","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1034\/j.1600-0625.2003.00089.x","article-title":"Regulation of PDGF and PDGF receptor in cultured dermal papilla cells and follicular keratinocytes of the human hair follicle","volume":"12","author":"Kamp","year":"2003","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.annder.2019.06.002_bib0265","first-page":"1331","article-title":"Chloracne-like drug eruption associated with sorafenib","volume":"10","author":"Pickert","year":"2011","journal-title":"J Drug Dermatol"},{"key":"10.1016\/j.annder.2019.06.002_bib0270","first-page":"449","article-title":"Perforating folliculitis, angioedema, hand-foot syndrome\u2013multiple cutaneous side effects in a patient treated with sorafenib","volume":"7","author":"Wolber","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.annder.2019.06.002_bib0275","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1346-8138.2010.00885.x","article-title":"Transient perforating folliculitis induced by sorafenib","volume":"37","author":"Minami-Hori","year":"2010","journal-title":"J Dermatol"},{"key":"10.1016\/j.annder.2019.06.002_bib0280","first-page":"E8","article-title":"Perforating folliculitis-like reaction related to sorafenib","volume":"93","author":"Eberst","year":"2014","journal-title":"Cutis"},{"key":"10.1016\/j.annder.2019.06.002_bib0285","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11523-009-0107-z","article-title":"The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents","volume":"4","author":"Sankhala","year":"2009","journal-title":"Target Oncol"},{"key":"10.1016\/j.annder.2019.06.002_bib0290","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1002\/cncr.27505","article-title":"Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors","volume":"118","author":"Balagula","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.annder.2019.06.002_bib0295","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1755-3768.2007.01154.x","article-title":"Papulopustular eruption after intravitreal bevacizumab (Avastin)","volume":"87","author":"Amselem","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.annder.2019.06.002_bib0300","first-page":"ECR44","article-title":"Skin lesions induced by bortezomib","volume":"90","author":"Pour","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.annder.2019.06.002_bib0305","first-page":"557","article-title":"Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib","volume":"16","author":"Rosenbaum","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annder.2019.06.002_bib0310","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.12010","article-title":"Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities","volume":"167","author":"Sinha","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2019.06.002_bib0315","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ajd.12124","article-title":"Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib","volume":"55","author":"Anforth","year":"2014","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.annder.2019.06.002_bib0320","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/02841860903104152","article-title":"Case studies showing clinical signs and management of cutaneous toxicity of the MEK1\/2\u00a0inhibitor AZD6244 (ARRY-142886) in patients with solid tumours","volume":"49","author":"Desar","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1016\/j.annder.2019.06.002_bib0325","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/j.1468-3083.2006.01723.x","article-title":"Follicular acneiform eruption induced by imatinib","volume":"20","author":"Mart\u00edn","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.06.002_bib0330","first-page":"21","article-title":"Eruptive milia and comedones during treatment with dovitinib","author":"Kimes K1","year":"2015","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.annder.2019.06.002_bib0335","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-4632.2012.5658.x","article-title":"Acute and severe acne in a patient treated with bevacizumab","volume":"52","author":"Molina-Ruiz","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.annder.2019.06.002_bib0340","first-page":"245","article-title":"Bevacizumab-associated sudden onset of multiple monomorphic comedones on the scalp successfully treated with 30\u00a0% salicylic acid peels","volume":"25","author":"Platsidaki","year":"2017","journal-title":"Acta Dermatovenerol Croat"},{"key":"10.1016\/j.annder.2019.06.002_bib0345","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1468-3083.2008.03078.x","article-title":"Perforating dermatosis in a patient receiving bevacizumab","volume":"23","author":"Vano-Galvan","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.06.002_bib0175","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/1523-1747.ep12471782","article-title":"Effects of 13-cis-retinoic acid, all-trans-retinoic acid, and acitretin on the proliferation, lipid synthesis and keratin expression of cultured human sebocytes in vitro","volume":"96","author":"Zouboulis","year":"1991","journal-title":"J Invest Dermatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819302418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819302418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:07:20Z","timestamp":1758971240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963819302418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0151963819302418"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2019.06.002","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9ruption nodulo-kystique induite par le soraf\u00e9nib","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2019.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}